An Effective COVID-19 Vaccine Needs to Engage T Cells
Karsten Sauer, Tim Harris
Abstract
Multiple lines of evidence support important roles for T cells in productive immune responses to COVID-19. In most SARS patients, B cell and nAB responses were relatively short lived (1-2 years) and prone to antigen escape, raising the possibility of re-infection. In contrast, T cell memory in survivors was long-lived (>6-17 years) (4-7, 19). It is well-known that T cells can engage antigen epitopes that are not targeted by B cells, including those derived from intracellular proteins, to
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyMedicineInternal medicineInfectious disease (medical specialty)OutbreakDiseaseSARS-CoV-2 and COVID-19 ResearchCAR-T cell therapy researchImmunotherapy and Immune Responses